Introduction
Mutations of PTEN, a tumor suppressor, have been found in human cancers arising from uterine endometrium, breast, ovary, prostate, brain, and melanocyte (Li et al., 1997; Risinger et al., 1997; Steck et al., 1997; Obata et al., 1998) . Although intensive studies have been undertaken to elucidate physiological functions of PTEN and mediators in the PTEN pathway, the processes are still not well understood (Dahia, 2000) . Recently Hong et al. (2000) searched for genes participating in the PTEN signaling pathway by means of cDNA microarrays, using invasive lung cancer cells in which exogenously transfected PTEN was constitutively expressed. However, the full range of biologically important mediators in this pathway is not fully characterized.
To identify additional mediators of the PTEN pathway, we also carried out cDNA microarray analyses using three PTEN-mutant endometrial-cancer cell lines infected either with control adenovirus or AdCAPTEN designed to express PTEN (MatsushimaNishiu et al., 2001) . In that study we identi®ed 99 genes that showed increased expression and 72 with reduced expression after introduction of PTEN. We had previously demonstrated that introduction of exogenous PTEN into ovarian-cancer cell lines suppressed cell growth and signi®cantly reduced expression of PTEN mRNA in some of those lines (Minaguchi et al., 1999) . On that basis we speculated that PTEN might be associated with ovarian carcinogenesis, and compared the data from our cDNA microarrays with the patterns of genes that had shown altered expression in primary ovarian cancers (Ono et al., 2000) .
Here we report further analysis of eight genes that might play important roles in the PTEN signaling pathway, and show evidence that two of them, EGR2 and BPOZ, are likely to be good candidates for mediating the growth-suppressive eect of PTEN.
Results

Transcriptional activation by PTEN
We selected six genes (EGR2, HCLS1, DUSP1, NFIL3, NDRG1, and APS) as well as two ESTs whose transcription we had found to be activated on cDNA microarrays hybridized with cDNA probe from cancer cells infected with AdCAPTEN (Matsushima-Nishiu et al., 2001) . Among these eight genes, expression of four function-known genes (EGR2, HCLS1, DUSP1, and NFIL3), and also the genes corresponding to the two ESTs, had been reduced in primary ovarian cancers (Ono et al., 2000) . The other two, APS and NDRG1, were chosen because their biological functions were interesting. To con®rm our previously reported results, we performed semi-quantitative RT ± PCR analyses. Figure 1 shows results using endometrial-cancer cells (HEC-151 and Ishikawa3-H-12) transfected with control adenovirus and corresponding cells with AdCAP-TEN. The results clearly indicated that all eight genes we examined were transcriptionally activated by introduction of PTEN to both cell lines although the expression levels varied. We also con®rmed that expression of PINK1 (one of the EST clones), BPOZ (the other EST clone), EGR2, HCLS1, DUSP1, and NFIL3 was signi®cantly reduced in the majority of the tumors we examined (Figure 2 ). Expression patterns of NDRG1 and APS varied from one tumor to another (data not shown).
Identification of a novel PTEN-induced putative kinase, PINK1
Since no full length cDNA for one of the ESTs we had chosen had not been isolated, we performed 5' rapid ampli®cation of cDNA ends (5'RACE) and obtained a cDNA sequence of 2600 bps encoding a 581-amino acid protein with a predicted molecular mass of 62.8 kD (Figure 3a ; GenBank accession No. AB053323). The size of this cDNA coincided with the 2.7-kb transcript indicated by Northern blot analysis (Figure 3b ), which was expressed ubiquitously but most abundantly in heart, skeletal muscle, and testis. Because motif analyses by the computer programs SMART (http://smart/embl-heidelberg/de/) and PSORT II Prediction (http://psort.nibb.ac.jp/ form2.html) implied that the protein was likely to have a putative serine/threonine protein kinase catalytic domain, we termed it PINK1, a novel PTENinduced putative kinase. The deduced PINK1 protein has some degree of homology with the product of the CG4523 gene of Drosophila melanogaster (43% identity in amino acids) as well as with hypothetical protein EEED8.9 of Caenorhabditis elegans (31% identity). Although the functions of these invertebrate genes are unknown, both proteins also contain putative serine/ threonine protein kinase catalytic domains.
Identification of splicing variants of BPOZ During our process of isolating a full-length cDNA for the other EST, Dai et al. (2000) reported the same gene and termed it BPOZ, whose deduced product contained an ankyrin repeat and two BTB/POZ domains although its biological function was unknown. Our Northern-blot analysis revealed that the BPOZ transcript was approximately 2.0 kb long, and was expressed in all 16 human adult tissues examined (data not shown). While con®rming the cDNA sequence we detected three alternatively spliced transcripts. Comparison of the cDNA sequences of these transcripts with sequences of BAC clones from human chromosome 3 allowed us to determine the genomic structure and the splicing patterns of the BPOZ gene (Figure 4a ), which consisted of 12 exons and covered an 8-kb genomic region. Three transcripts were generated by alternative splicing of exon 2; among three segments from 5' to 3' of exon 2 (46, 28, and 35 bp; Figure 4b ), the BPOZ type1 transcript contained the 46 and 28-bp fragments, type2 contained the 28 and 35-bp fragments, and type 3 had only the 28-bp fragment. A stop codon appears in exon 12 in all three types of transcript. We termed the gene products BPOZ-1, BPOZ-2, and BPOZ-3 (GenBank accession Nos. AB053324, AB053325, and AB053326 respectively). BPOZ-2 contains two ankyrin repeats; BPOZ-3 has only one, and BPOZ-1 none (Figure 4b ; underline). BPOZ-2 and -3 have two Figure 1 Semi-quantitative RT ± PCR analysis of mRNAs from two endometrial-cancer cell lines infected with AdCA (empty vector) or AdCAPTEN and collected 24 h later. The integrity of each RNA template was controlled through ampli®cation of GAPDH Two putative tumor suppressors involved in the PTEN pathway M Unoki and Y Nakamura complete BTB/POZ domains but one of the two BTB/ POZ domains in the protein encoded by type1 is incomplete (Figure 4b ; italic). BPOZ-2 was most predominantly expressed in peripheral blood leukocytes and endometrial-cancer cell lines, followed by BPOZ-3; and -1 was expressed at a very low level ( Figure 4c ). We examined induction of BPOZ by exogenous PTEN by means of semi-quantitative RT ± PCR; that experiment showed that BPOZ-2 and -3 were both strongly induced, so we analysed further the proteins encoded by BPOZ-2 and -3 transcripts (Figure 4d ). These products possessed some degree of similarity with two function-unknown yeast proteins, C13D6.04C of Schizosaccharomyces pombe (29% identity) and YIL001W of Saccharomyces cerevisiae (26% identity). Each of these yeast molecules contains two ankyrin repeats in the N-terminal region and two BPB/POZ domains in the C terminal region, as does human BPOZ-2.
Colony-formation assays
To examine HCLS1, EGR2, BPOZ-2 and 3, NDRG1, PINK1, DUSP1, NFIL3, and APS for potential growth-suppressive eects, we cloned each of the genes into expression vector pcDNA3.1 (+ and 7), and performed colony-formation assays using two endometrial-cancer cell lines (Sawano and Ishikawa3-H-12), one ovarian-cancer cell line (MDAH2774), and two Expression of PINK1 in adult human tissues on Northern blots. PINK1 is expressed ubiquitously and at high levels in heart, skeletal muscle, and testis Oncogene Two putative tumor suppressors involved in the PTEN pathway M Unoki and Y Nakamura colon-cancer cell lines (SW480 and LoVo). Endogenous expression levels of these genes varied in the cell lines we used in this study (data not shown). HCLS1 expression was not detectable in SW480, Sawano and MDAH2774 by RT ± PCR. Transfection of EGR2, BPOZ-2 or BPOZ-3 brought about signi®cant decreases in colony numbers, suggesting growth-suppressive activity (Table 1) ; the six other candidate genes showed no eect on cell growth (data not shown). EGR2 suppressed cell growth in all except SW480; BPOZ-2 or -3 suppressed growth of all cell lines except Ishikawa3-H-12. Mutations or variations of BPOZ were found in Sawano, Ishikawa3-H-12, and MDAH2774, but none of them were likely to eect on functions of the gene (data not shown). No genetic alteration of EGR2 was found in any of the cell lines used (data not shown).
Subcellular localization and stable transformants of BPOZ
To investigate the subcellular localization of BPOZ protein, plasmid DNAs designed to express FLAGtagged (at C-terminal region) BPOZ-2 or -3 were transfected to several cell lines. Initially we examined expression by Western blotting, and discovered that proteins of two dierent sizes were translated from each construct: approximately 57 and 40-kD molecules from pFLAG-BPOZ-2, and 54 and 40-kD products from pFLAG-BPOZ-3 (Figure 5a ). The smaller protein Two putative tumor suppressors involved in the PTEN pathway M Unoki and Y Nakamura from each construct could have been generated by proteolytic breakdown or translation from the ATG codon in exon 5 (the expected size of the protein from this ATG would be 40.2 kD), although the sequences around that ATG do not match well to the Kozak consensus. Figure 5b shows the subcellular localization of FLAG-tagged BPOZ-2 and -3 in Cos7 cells. Both types of protein were localized in cytoplasm here, and also in other cells examined (data not shown).
To investigate the physiological function(s) of BPOZ, we established transfectants stably expressing BPOZ-2 and -3, using the SW480 cell line. No morphological changes were observed, but the rates of growth of both transfectants slowed signi®cantly in comparison to control cells (mock vs BPOZ-2, P=0.0006; mock vs BPOZ-3, P=0.0181 by the Student's t-test) (Figure 5c ). Subsequently we examined eects of BPOZ on cell cycles in the same transfectants by¯ow cytometry. Using aphidicolin, we synchronized the cells at the G 1 phase and released them from arrest by washing with PBS. As shown in Figure 5d , elongation of S phase and apparent delay of G 1 /S transition were observed in BPOZ transfectants.
Growth enhancement by anti-sense oligonucleotides for BPOZ and EGR2
To con®rm the apparent growth-suppressive eects of BPOZ and EGR2, we attempted to suppress expression of these two genes using anti-sense (BPOZ 1-AS1, EGR2 AS2) or sense (BPOZ 1-S1, EGR2 S2) oligonucleotides by transfecting each of the four oligonucleotides into SW480 cells by lipofection. Transfection eciency of oligonucleotides by lipofection was estimated to be more than 95% by¯ow cytometry as well as by¯uorescent microscopy using of FITC-labeled oligonucleotides (Figure 6a ). We also examined the time-span of the FITC-labeled oligonucleotides. Ninety-six hours after lipofection, they were still detectable in more than 90% of the cells (data not shown). Because BPOZ 1-AS1 corresponded to DNA sequences contained in all three types of BPOZ transcript, we expected them to suppress transcription of all variants of the BPOZ gene. 12 h after transfection, we extracted mRNA and examined expression levels of BPOZ and EGR2 by semiquantitative RT ± PCR. Our results, shown in Figure  6b , clearly demonstrated signi®cant suppression of expression of EGR2 and also all three transcripts of BPOZ. As expected, 96 h later the numbers of cells transfected with the anti-sense oligonucleotides were markedly greater than those treated with the paired sense oligonucleotides (P50.01; Figure 6c ).
Discussion
Although most tumor suppressors appear to be involved directly in regulation of the cell cycle, PTEN is located in cytoplasm and regulates cell growth through its function as a phosphatase; i.e., it modulates the phosphatidylinositol-3-kinase (PI3K) pathway by genes that had been down-regulated in primary ovarian tumors (Ono et al., 2000) . Although mutation of PTEN is not a common feature among ovarian cancers (Maxwell et al., 1998; Yokomizo et al., 1998) , we had demonstrated previously that endogenous mRNA expression of PTEN was signi®cantly reduced in some ovarian-cancer cell lines and also that exogenous PTEN suppressed growth of such cells (Minaguchi et al., 1999) . Therefore we considered that PTEN might be associated with ovarian carcinogenesis through unknown pathway(s). By comparing 99 genes that were up-regulated by introduction of PTEN into the cancer cells with those down-regulated in primary ovarian cancers, we identi®ed four genes and two ESTs that behaved the same way in both series of experiments. For the present study we also included two additional genes, NDRG1, and APS, for further analysis because they were strongly induced by PTEN and because the former had been reported as a novel candidate for metastatic suppression (Guan et al., 2000) and APS was known to inhibit PDGF-induced mitogenesis (Yokouchi et al., 1999) .
We ®rst determined the full-length cDNA sequences of the two EST clones. Although we thought one of the novel genes, which we termed PINK1, represented a good candidate in view of its putative serine/ threonine protein kinase catalytic domain, we detected no growth-suppressive function of its product. However, since PINK1 lies on chromosome 1p31.1-34.3, where losses of heterozygosity (LOH) are frequently observed in endometrial cancers (Arlt et al., 1996) , this gene warrants further investigation. Because PINK1 mRNA is expressed ubiquitously among adult tissues examined, the PINK1 gene may play important fundamental roles in cell. When we isolated the fulllength cDNA of the second EST, we noticed that the sequence was identical to BPOZ (Dai et al., 2000) , a gene that contains an ankyrin repeat and two BTB/ POZ domains.
Subsequently we performed colony-formation assays to examine whether each of the eight genes examined would suppress growth of cancer cells. Transfection of each cDNA into ®ve dierent cancer-cell lines disclosed possible growth-suppressive eects of two of them, EGR2 and BPOZ (both type 2 and -3 transcripts); the remaining six genes had no in¯uence on the number of the colonies achieved in any of the cell lines tested. The growth-suppressive eect of the two genes was observed not only in the endometrial-and ovariancancer cell lines, but also in the colon-cancer cell lines. This suggested that the EGR2 and BPOZ might have tumor-suppressive function for a relatively-wide range of human cancers.
The EGR2 gene belongs to a multi-gene family encoding C2H2-type zinc-®nger proteins (Joseph et al., 1988) and may play a role in the regulation of cellular proliferation (Rangnekar et al., 1990) . Egr2 (7/7) mice display disrupted hindbrain segmentation and development, and Schwann-cell dierentiation is blocked at an early stage (Topilko et al., 1994) . In humans, a defect of this gene causes congenital hypomyelinating neuropathy and type 1 CharcotMarie-Tooth syndrome (Warner et al., 1998) . EGR2 is associated with the onset of myelination in the peripheral nervous system (Zorick et al., 1996) and is activated during G 0 /G 1 transition in cultured cells (Chavrier et al., 1988) . Recently, a few reports implicated an important role of EGR2 in apoptosis regulation and also its eect to the upregulation of Fas ligand in T cells (Mittelstadt and Ashwell, 1999; Dzialo-Hatton et al., 2001 ). EGR1, a protein with a high degree of sequence homology with EGR2, has a bi-directional eect on cell growth; it can function as an oncogene (Eid et al., 1998; Abdulkadir et al., 2001) and also as a tumor suppressor Huang et al., 1997) . We suspect that EGR2 may also have multiple functions.
Evolutionary conservation is indicated by the evidence that BPOZ is in some degree similar to proteins in yeast strains that also contain two ankyrin repeats at the N-terminal and two BPB/POZ domains at the C-terminal. Western blots using FLAG-tagged BPOZ-2 and -3 indicated that proteins of two dierent sizes were translated from each of the constructs. Since both large and small versions of the proteins were expressed during colony-formation assays, and in each case both sizes were suppressed in experiments using antisense oligonucleotide for either BPOZ-2 or BPOZ-3, it is unclear which of the forms is/are required to suppress cell growth. Flow cytometry using cells that stably expressed BPOZ-2 or BPOZ-3 indicated that BPOZ could regulate cell growth especially at the G 1 /S transition.
BPOZ-2 protein contains two ankyrin repeats and two BPB/POZ domains. INK4-family proteins that block the G 1 -to-S transition are known to include ankyrin repeats, and since mutations in the ankyrinrepeat of p16/INK4a protein have been noted in many types of cancer (Borg et al., 1996) , ankyrin repeats appear to play crucial roles. BPB/POZ domains are observed in many cell-growth regulators that include DIP (de la Luna et al., 1999) , APM-1 (Reuter et al., 1998) , Plzf (Barna et al., 2000) , and FAZF (Hoatlin et al., 1999) , and are considered to be essential for protein ± protein interactions (Bardwell and Treisman, 1994) . Therefore the BPOZ protein is likely to interact with other proteins to regulate the cell cycle. We believe that our data contribute to an improved understanding of the physiological role of PTEN, by suggesting that ERG2 and BPOZ may serve as tumorsuppressive mediators in the PTEN signaling pathway.
Materials and methods
Cell lines
Ishikawa3-H-12 cells were obtained from Tsukuba University (Tsukuba, Japan). Sawano cells were obtained from the RIKEN Gene Bank (Tsukuba, Japan). MDAH2774, SW480, LoVo, and Cos-7 cells were obtained from the American Type Culture Collection (Manassas, VA, USA). HEC-151 cells were obtained from Kitasato University (Sagamihara, Oncogene Two putative tumor suppressors involved in the PTEN pathway M Unoki and Y Nakamura Japan). Ishikawa3-H-12, Sawano, and HEC-151 cells were maintained in Eagle's minimal essential medium with 10% fetal bovine serum (FBS); MDAH2774 and SW480 cells were maintained in Leibovitz's L-15 medium with 10% FBS; LoVo cells were maintained in Ham's F12 medium with 10% FBS; and Cos-7 cells were maintained in Dulbecco's modi®ed Eagle's medium with 10% FBS.
Semi-quantitative RT ± PCR and Northern analyses
HEC-151 and Ishikawa3-H-12 cells were infected with AdCAPTEN or AdCA at a MOI of 50 plaque-forming units/cell for 1 h and harvested 24 h later. Ovarian-cancer tissues, along with corresponding non-cancerous ovary, had been excised during surgery with informed consent from eight patients. Three of the tumors (Nos. I ± III) were histologically diagnosed as mucinous type and ®ve (Nos. IV ± VIII) as serous type (Ono et al., 2000) . Preparation of total RNAs and RT ± PCR experiments were performed as described previously (Matsushima-Nishiu et al., 2001; Ono et al., 2000) . Human multiple-tissue Northern blots (Clontech) were hybridized with partial cDNA fragments of PINK1 or BPOZ that had been labeled by random-oligonucleotide priming. Conditions of hybridization and washing were described previously (Nakagawa et al., 2000) .
Isolation and DNA sequencing of the human PINK1 cDNA Target cDNAs on our microarray slides were chosen on the basis of information from the Unigene database. PINK1 was spotted on the glass slides as an EST fragment. We determined PINK1 structure performing EST walking and 5' rapid ampli®cation of cDNA ends (5'RACE) using the Marathon cDNA ampli®cation kit (Clontech, Palo Alto, CA, USA) according to the manufacturer's protocols.
Splicing variants of BPOZ
To investigate splice variants of the BPOZ transcripts we performed PCR experiments using primers corresponding to DNA sequences of exon 1 for forward primer (5'-ATGGACACCAGCGACCTGTT-3') and exon 3 for reverse primer (5'-TAGAGTACCAGC TCCTCGTG-3').
Colony-formation assays
The entire coding cDNA sequences of each of the eight genes chosen for study were ampli®ed by PCR using KOD-Plus-(TOYOBO) and cloned into the multi-cloning sites of pcDNA3.1 (+) and (7) vectors (Invitrogen). SW480, LoVo, MDAH2774, Sawano, and Ishikawa3-H-12 cells were plated and each was transfected by lipofection (FuGENE6 Transfection Regent; Roche) with 12 ug of either pcDNA3.1 (+) or (7) containing one of the eight cDNAs. Twenty-four hours later, the media were replaced with an optimal concentration of G418 (GIBCO)-containing medium. Cells were cultured for two weeks and stained by Giemsa's solution (MERCK).
Western analysis and immunofluorescent staining of BPOZ
The entire coding cDNA sequences of BPOZ corresponding to type 2 and -3 transcripts were cloned into the multi-cloning site of pFLAG-CMV vector (Kodak), in which FLAG tag was added to the C-terminal region. Western analysis and immuno¯uorescent staining were performed as described previously (Oda et al., 2000) .
Stable BPOZ transfectants
SW480 cells were seeded and transfected with pcDNA3.1 (+)-BPOZ-2 or -3, or with an empty vector as control, using FuGENE6 Transfection Reagent, according to the manufacturer's protocol. Cells were cultured for *1 month in medium containing 1 mg/ml of G418. Individual clones were isolated using cloning cylinders. The cell clones that expressed BPOZ (as con®rmed by RT ± PCR) were maintained in medium containing 1 mg/ml of G418 and used for further investigations.
Flow cytometry
SW480 cells over-expressing BPOZ-2 or -3, and mock cells, were plated at densities of 2610 5 cells/60-mm dish and their cell cycles were synchronized in medium containing 5 ug/ml aphidicolin (Sigma) and 1 mg/ml G418. Twenty-four hours after the drug was added, cells were washed three times with PBS and maintained in medium containing 1 mg/ml G418. Every six hours, cells were trypsinized, collected, and treated with Cycle TEST PLUS (Becton Dickinson) according to the manufacturer's protocol. Flow cytometrical anaysis was performed as described previously (Matsushima-Nishiu et al., 2001 ).
Anti-sense oligonucleotides
To examine the eect of depletion of endogenous BPOZ or EGR2, we prepared HPLC-puri®ed anti-sense oligonucleotides phosphorothioate (BPOZ 1-AS1: TGTCCAG-CATGTTGGC; EGR2 AS2: GGTCATCATTTGCTCC) and also, as controls, sense oligonucleotides phosphorothioate (BPOZ 1-S1: GCCAACATGCTGGACA; EGR2 S2: GATGACCGCCAAGGCC) according to the sequences of the BPOZ or EGR2 genes. FITC-labeled AS was used for evaluating the eciency of nuclear incorporation. Anti-sense and sense oligonucleotides phosphorothioate (1 uM) were transfected with Lipofectin reagent (GIBCO ± BRL) for 12 h. We isolated RNA from the cells 12 h later, and counted or stained them after 96 h.
